Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

333.34USD
18 Apr 2019
Change (% chg)

$-9.63 (-2.81%)
Prev Close
$342.97
Open
$346.40
Day's High
$347.55
Day's Low
$332.22
Volume
1,920,372
Avg. Vol
750,283
52-wk High
$442.00
52-wk Low
$281.89

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $35,789.33
Shares Outstanding(Mil.): 107.37
Dividend: --
Yield (%): --

Financials

  REGN.O Industry Sector
P/E (TTM): 16.10 109.48 62.40
EPS (TTM): 20.70 -- --
ROI: 26.52 7.96 11.78
ROE: 31.90 8.11 12.61

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Apr 08 2019

UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up

April 8 Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Apr 08 2019

Alnylam, Regeneron to partner for RNAi treatments

April 8 Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Apr 08 2019

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

UPDATE 2-Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

March 11 The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Mar 11 2019

Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

March 11 The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs.

Mar 11 2019

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

Feb 25 2019

UPDATE 2-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

Feb 25 2019

CORRECTED-UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report

Feb 25 A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Feb 25 2019

CORRECTED-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Feb 25 2019

Earnings vs. Estimates